Navigation Links
Advanced targeted therapies effective as first-line treatment for lung cancer
Date:8/1/2009

CLINICAL OUTCOME WITH ERLOTINIB: RESULTS FROM THE PHASE III PLACEBO-CONTROLLED SATURN STUDY OF MAINTENANCE THERAPY FOR ADVANCED NSCLC (ABSTRACT # B9.1)

In another segment of the SATURN study, researchers further examined the efficacy of erlotinib as a maintenance therapy in non-progressive disease patients after first-line platinum-containing chemotherapy. Currently the indications for erlotinib are limited to its use as a second- or third-line agent after failure of first-line chemotherapy.

To expand the potential for the use of erlotinib, Wolfram Brugger, M.D., Ph.D., head of the Department of Hematology, Oncology and Immunology at Schwarzwald-Baar Clinic in Germany, and his team of researchers conducted the phase III, placebo-controlled SATURN study to evaluate the efficacy of erlotinib as a maintenance therapy.

Dr. Brugger enrolled a total of 889 non-small cell lung cancer (NSCLC) patients and treated them with either 150mg/day of erlotinib or placebo after four cycles of platinum-based doublet chemotherapy. Researchers evaluated molecular markers including EGFR protein and EGFR gene copy number, EGFR- and KRAS-mutations and EGFR polymorphism in order to potentially identify predictive markers for erlotinib therapy.

Both arms of the trial were well represented in patient and disease characteristics, specifically regarding biomarker status. Dr. Brugger and his team determined that the use of erlotinib provided a clinical benefit in terms of both progression-free and overall survival for all patients, regardless of the status of biomarkers.

"This study demonstrates the tremendous potential for erlotinib and the potential for its expanded use as a maintenance therapy," says Dr. Brugger. "The addition of an effective tool physicians can use to maintain a cancer-free state in their patients is crucial to prolonged survival."

Dr. Brugger will present this study on Saturday, August 1 at 2:30 pm PT in Moscon
'/>"/>

Contact: Liz Wulderk
lwulderk@spectrumscience.com
443-506-1931
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Smith & Nephew Highlights Advanced Wound Management Progress
2. Patient safety advanced by revised heparin standards
3. AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer
4. Penile Prosthesis Surgery Infection Rates Reduced With The No-Touch Technique By Dr. J. Francois Eid of Advanced Urological Care
5. Leading Independent Analyst Firm States Silver Creek Systems Holds A Virtual Monopoly In Delivering Advanced Product Data Quality Capabilities
6. Surgery remans an option for advanced lung cancer
7. Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
8. Hendrick Health System Deploys Sentillions Tap & Go Advanced Authentication Solution
9. Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer
10. Marienkrankenhaus Hamburg Installs Visage(R) CS Enterprise Wide Advanced Visualization Solutions
11. Advanced Bag Design for Cryopreservation: The New CryoMACS(R) Freezing Bag
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... Elfster.com, the top-rated Secret Santa generator, ... plans to publicize its gift exchange generator technology and ... as the leader in Secret Santa online gift exchanges, ... markets can see the opportunities as well. , "We ... Peter Imburg, CEO of Elster.com. "With Christmas and Valentine’s ...
(Date:3/29/2015)... Metamora, MI. (PRWEB) March 29, 2015 ... Hospital , offers comprehensive endometriosis treatment. Secondary to ... that area a closer hospital option. They continue ... and McLaren Oakland. , Endometriosis is often ... the inside of the uterus (the endometrium) grows outside ...
(Date:3/29/2015)... 2015 Telerad RxDx Multispecialty Healthcare ... NABH Accreditation on 11th January 2015. The accreditation ... Healthcare Providers) comes as a true recognition of ... Telerad RxDx., With Telerad RxDx being the first ... NABH, marks a major achievement and a significant ...
(Date:3/29/2015)... 2015 The Claudia Cohen Research ... announce today that Dr. Beth Y. Karlan has ... Cohen Research Foundation Prize for Outstanding Gynecologic Researcher. The ... Gynecologic Oncology 46th Annual Meeting on Women's Cancer in ... Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer ...
(Date:3/29/2015)... York, NY (PRWEB) March 29, 2015 ... treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) pending in the ... scheduled the litigation’s next Case Management Conference for ... that the meeting will address the progress of ... who allegedly experienced heart attacks, strokes and other ...
Breaking Medicine News(10 mins):Health News:Gift Exchange Generator Promotion Achieves Early Success, Announces Elfster 2Health News:Women's Excellence Affiliates with Beaumont Hospital, Treats Endometriosis 2Health News:NABH Accreditation for Telerad RxDx – Whitefield. 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3
... -- If you have a sweet tooth, you may have a ... a series of experiments that compared people,s tastes for sweets with ... were more likely to volunteer to help another person in need, ... test found that people tend to believe that people who like ...
... Gardner HealthDay Reporter , THURSDAY, Oct. 27 (HealthDay News) ... cancer by more than half in people who are predisposed to ... tablets of 300 milligrams each also cut the risk of other ... and other cancers, according to research published in the Oct. 28 ...
... lives by detecting very small tumors. However, it fails ... distinguish between benign and malignant disease. New research published ... provides a new and potentially more sensitive method using ... sensors. A team of researchers from University of ...
... Gardner HealthDay Reporter , THURSDAY, Oct. 27 (HealthDay ... rudimentary speech therapy after suffering a massive stroke at the ... spent a year-and-a-half completely isolated, unable to communicate, socialize or ... Labs in Texas, one of a handful of organizations cropping ...
... THURSDAY, Oct. 27 (HealthDay News) -- Trying to bolster ... achievement could actually make you feel depressed, according to ... U.S. college undergraduates and 2,780 high school students in ... when they assessed themselves accurately, but participants who rated ...
... why chemotherapy agents target cancer, scientists at Dana-Farber Cancer ... effective the drugs will be by determining whether a ... In a study published online by the journal ... cancer cells that are on the verge of self-destruction ...
Cached Medicine News:Health News:Will Eating Sweets Make You Sweeter? 2Health News:Daily Aspirin May Help Prevent Colon Cancer for Those at High Risk 2Health News:Daily Aspirin May Help Prevent Colon Cancer for Those at High Risk 3Health News:Speech Therapy Key to Stroke Rehab, But Many Miss Out 2Health News:Speech Therapy Key to Stroke Rehab, But Many Miss Out 3Health News:Honest Self-Assessment Better Than False Praise 2Health News:Research makes it possible to predict how cancers will respond to chemo 2Health News:Research makes it possible to predict how cancers will respond to chemo 3
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... in Santa Ana, California is a ... market for which is estimated at $22 billion in the ... includes the use of FDA-approved Naltrexone in a specially compounded ... (excluding Australia and New ...
(Date:3/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... issuance of an aggregate of 30,000 stock options to ... of 120,500 stock options to employees and consultants of ... years and will be exercisable for a period of ... stock option. About Covalon Covalon Technologies ...
(Date:3/27/2015)... /PRNewswire/ - Medicure Inc. (the "Company") (TSXV:MPH, OTCQB:MCUJF) announces ... grant of an aggregate of 236,070 options to certain ... the Company pursuant to the Company,s Stock Option Plan. ... the tenth anniversary of the date of grant, 5,000 ... the date of grant and 50,000 are set to ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Covalon Announces Issuance of Stock Options 2
... and SUNNYVALE, Calif., April 14 ,Pharmacyclics, Inc. (Nasdaq: ... program evaluating PCI-32765, an orally available, selective,inhibitor of ... (BCR),modulated diseases such as lymphomas and autoimmune diseases. ... the American Association for Cancer,Research (AACR) being held ...
... HUYA,s Integrated Co-Development Model for ... China-sourced Drug ... International,(HUYA), the leader in U.S./China pharmaceutical co-development, today,announced the ... the U.S. FDA for a development-stage compound sourced,from China. ...
Cached Medicine Technology:Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases 2Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases 3HUYA Bioscience Int'l Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound 2HUYA Bioscience Int'l Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound 3HUYA Bioscience Int'l Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound 4
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... fixed pipette is ideal for ... volume. Fixed volume FInnpipettes offer ... as other Finnpipette Digital pipettes: ... blow-out (1-40ul), Soft-touch tip ejection, ...
... The microprocessor controlled, Blanketrol II ... system provides effective patient warming ... system! The Blanketrol II offers ... flow rates of any hyper-hypothermia ...
Medicine Products: